Comprehensive Report on the Investigational Drug YYC-506

I. Introduction to YYC-506

YYC-506 is an investigational small molecule pharmaceutical agent, classified as an antihyperlipidemic, currently under development by the South Korean firm Yooyoung Pharm Co. Ltd..[1] The compound has been designated as a New Molecular Entity (NME).[2] The primary therapeutic objective for YYC-506 is the management of complex dyslipidemias. It is specifically being evaluated for patients who have achieved adequate control of their low-density lipoprotein cholesterol (LDL-C) levels through statin therapy, typically with atorvastatin, but continue to exhibit elevated plasma triglycerides (TG) and/or sub-optimal levels of high-density lipoprotein cholesterol (HDL-C).[3] This focus addresses a significant residual cardiovascular risk often observed in patients despite effective LDL-C lowering.

Yooyoung Pharm Co. Ltd. is identified as both the originator and the sole active organization responsible for the clinical development of YYC-506.[1] The drug is currently in the advanced stages of clinical investigation, having reached Phase 3 trials for the treatment of hyperlipidemias in South Korea. Additionally, there are indications of Phase 2 development for dyslipidemias in the United States, suggesting a potential strategy for broader market introduction pending successful trial outcomes.[1]